These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

428 related items for PubMed ID: 20615933

  • 1. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia.
    Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M, Hough D.
    J Psychopharmacol; 2011 May; 25(5):685-97. PubMed ID: 20615933
    [Abstract] [Full Text] [Related]

  • 2. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
    Li H, Rui Q, Ning X, Xu H, Gu N.
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun 01; 35(4):1002-8. PubMed ID: 21315787
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study.
    Gopal S, Hough DW, Xu H, Lull JM, Gassmann-Mayer C, Remmerie BM, Eerdekens MH, Brown DW.
    Int Clin Psychopharmacol; 2010 Sep 01; 25(5):247-56. PubMed ID: 20389255
    [Abstract] [Full Text] [Related]

  • 4. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension.
    Tzimos A, Samokhvalov V, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M.
    Am J Geriatr Psychiatry; 2008 Jan 01; 16(1):31-43. PubMed ID: 18165460
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial.
    Berwaerts J, Liu Y, Gopal S, Nuamah I, Xu H, Savitz A, Coppola D, Schotte A, Remmerie B, Maruta N, Hough DW.
    JAMA Psychiatry; 2015 Aug 01; 72(8):830-9. PubMed ID: 25820612
    [Abstract] [Full Text] [Related]

  • 6. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia.
    Pandina GJ, Lindenmayer JP, Lull J, Lim P, Gopal S, Herben V, Kusumakar V, Yuen E, Palumbo J.
    J Clin Psychopharmacol; 2010 Jun 01; 30(3):235-44. PubMed ID: 20473057
    [Abstract] [Full Text] [Related]

  • 7. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia.
    Hough D, Lindenmayer JP, Gopal S, Melkote R, Lim P, Herben V, Yuen E, Eerdekens M.
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Aug 31; 33(6):1022-31. PubMed ID: 19481579
    [Abstract] [Full Text] [Related]

  • 8. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.
    Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M.
    Schizophr Res; 2010 Feb 31; 116(2-3):107-17. PubMed ID: 19959339
    [Abstract] [Full Text] [Related]

  • 9. A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia.
    Coppola D, Liu Y, Gopal S, Remmerie B, Samtani MN, Hough DW, Nuamah I, Sulaiman A, Pandina G.
    BMC Psychiatry; 2012 Mar 28; 12():26. PubMed ID: 22455454
    [Abstract] [Full Text] [Related]

  • 10. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
    Patrick DL, Burns T, Morosini P, Gagnon DD, Rothman M, Adriaenssen I.
    Clin Ther; 2010 Feb 28; 32(2):275-92. PubMed ID: 20206786
    [Abstract] [Full Text] [Related]

  • 11. Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial.
    Bossie CA, Sliwa JK, Ma YW, Fu DJ, Alphs L.
    BMC Psychiatry; 2011 May 10; 11():79. PubMed ID: 21569242
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies.
    Emsley R, Berwaerts J, Eerdekens M, Kramer M, Lane R, Lim P, Hough D, Palumbo J.
    Int Clin Psychopharmacol; 2008 Nov 10; 23(6):343-56. PubMed ID: 18854723
    [Abstract] [Full Text] [Related]

  • 13. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.
    Kramer M, Simpson G, Maciulis V, Kushner S, Vijapurkar U, Lim P, Eerdekens M.
    J Clin Psychopharmacol; 2007 Feb 10; 27(1):6-14. PubMed ID: 17224706
    [Abstract] [Full Text] [Related]

  • 14. Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison.
    Fu DJ, Bossie CA, Sliwa JK, Ma YW, Alphs L.
    Int Clin Psychopharmacol; 2014 Jan 10; 29(1):45-55. PubMed ID: 24113628
    [Abstract] [Full Text] [Related]

  • 15. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
    Fu DJ, Bossie CA, Kern Sliwa J, Ma YW, Alphs L.
    Clin Schizophr Relat Psychoses; 2014 Jul 10; 8(2):101-9, 109A. PubMed ID: 23446197
    [Abstract] [Full Text] [Related]

  • 16. Design and rationale of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study: a novel comparative trial of once-monthly paliperidone palmitate versus daily oral antipsychotic treatment for delaying time to treatment failure in persons with schizophrenia.
    Alphs L, Mao L, Rodriguez SC, Hulihan J, Starr HL.
    J Clin Psychiatry; 2014 Dec 10; 75(12):1388-93. PubMed ID: 25375367
    [Abstract] [Full Text] [Related]

  • 17. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia.
    Gopal S, Gassmann-Mayer C, Palumbo J, Samtani MN, Shiwach R, Alphs L.
    Curr Med Res Opin; 2010 Feb 10; 26(2):377-87. PubMed ID: 20001492
    [Abstract] [Full Text] [Related]

  • 18. Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia.
    Canuso CM, Bossie CA, Amatniek J, Turkoz I, Pandina G, Cornblatt B.
    Early Interv Psychiatry; 2010 Feb 10; 4(1):64-78. PubMed ID: 20199482
    [Abstract] [Full Text] [Related]

  • 19. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study.
    Alphs L, Benson C, Cheshire-Kinney K, Lindenmayer JP, Mao L, Rodriguez SC, Starr HL.
    J Clin Psychiatry; 2015 May 10; 76(5):554-61. PubMed ID: 25938474
    [Abstract] [Full Text] [Related]

  • 20. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia.
    Pandina G, Lane R, Gopal S, Gassmann-Mayer C, Hough D, Remmerie B, Simpson G.
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jan 15; 35(1):218-26. PubMed ID: 21092748
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.